• 1. Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 2. Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
WANG Xin, Email: wangxin@wchscu.edu.cn
Export PDF Favorites Scan Get Citation

Colorectal cancer (CRC) is a prevalent malignant tumor worldwide. With the development of medical technology, the treatment strategies of CRC are constantly improving and updating. The aim of treating CRC is not only to improve outcomes but also to maintain organ function and enhance quality of life. For patients with locally advanced rectal cancer, a variety of neoadjuvant treatment options are available and it is important to choose an individualized strategy. Immune checkpoint inhibitors have become an important part of the first- and posterior-line treatment for patients with deficient mis-match repair or high microsatellite instability colorectal cancer in metastatic colorectal cancer, and the emergence of new targets and drugs has further improved treatment efficacy and long-term survival. Furthermore, an increasing number of studies have confirmed the potential the value of predicting and guiding treatment for minimal residual disease. This article summarizes the representative research results, guideline updates, and important academic conference reports in the field of colorectal cancer.

Citation: DUAN Jiayu, TANG Yuanling, GU Shiyuan, WANG Xin. Advances in the treatment of colorectal cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(5): 523-529. doi: 10.7507/1007-9424.202404039 Copy